Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (Nasdaq: CLDI) is a clinical-stage biopharmaceutical company focused on oncolytic virotherapy, developing stem cell-based platforms designed to enhance the delivery of cancer-killing viruses to tumor sites. The company reached the public markets through its merger with FLAG Pioneer Merger Corp, a blank-check vehicle sponsored by FLAG Pioneer LLC that completed its IPO in 2021. Calidi filed this Form 10-Q with the SEC on August 21, 2023, disclosing its financial position and operational updates as it progressed through its de-SPAC transition. The company operates in the oncology and cell-based therapeutics sector, with its pipeline targeting solid tumors including glioblastoma. Visit SpacDesk and sign up for full data, filings, and analytics on Calidi Biotherapeutics and hundreds of other SPAC-linked companies.